Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD. The post How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won appeared first on Investor's Business Daily.
CryptoAlerta — análise de criptomoedas e mercado em tempo real